Reach for Korlym to fight back withSIGNIFICANT REDUCTIONS IN WEIGHT AND DEPRESSION

Patients treated with Korlym experienced a significant 5.7% (6.3 kg) reduction in mean body weight at Week 24/ET1,a,b,*

Graph showing Korlym patients achieving significant 5.7% reduction in weight at Week 24/ET in the SEISMIC study.

Most patients experienced reductions in body weight1:

More than 50% of patients reduced body weight by ≥5% (n=24/46) in the SEISMIC study.

of patients reduced
body weight by ≥5%
(n=24/46)

More than 25% of patients reduced body weight by ≥10% (n=12/46) in the SEISMIC study.

of patients reduced
body weight by ≥10%
(n=12/46)

Because of the variability in clinical presentation and variability of response in the open-label trial, it is uncertain whether the change in body weight could be ascribed to the effects of Korlym.2

aIn the modified intent-to-treat population, defined as patients who received >30 days of study medication.1

bMean baseline BMI was 35.7 kg/m2 in the intent-to-treat population.1

Patients experienced significant improvements in depression†

60% of patients with mild-to-severe depression improved to minimal depression by Week 24 (n=14/24)3

Graph showing Korlym patients achieving significant improvements in depression at Week 24/ET in the SEISMIC study.

†Because of the variability in clinical presentation and variability of response in the open-label trial, it is uncertain whether the change in psychiatric symptoms could be ascribed to the effects of Korlym.2

BDI-II, Beck Depression Inventory®-II.

References:
  1. Fleseriu M, Biller BMK, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049. doi:10.1210/jc.2011-3350
  2. Korlym Prescribing Information. Corcept Therapeutics, Inc; 2019.
  3. Data on file. Clinical Study Report: C1073-400. Corcept Therapeutics, Inc.
  4. Data on file. DM Cohort 7% line source doc. Corcept Therapeutics, Inc.